BusinessDermira to Present Data from DRM01 and DRM04 Clinical Programs at Fall Clinical Dermatology ConferenceBy Nasdaq OMXOct 13, 2016, 11:31 AM UTC
BusinessCIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque PsoriasisBy Nasdaq OMXOct 3, 2016, 6:00 AM UTC
BusinessDermira Presents Data from DRM04 Phase 3 Clinical Program in Late-Breaking News Session at European Academy of Dermatology and Venereology CongressBy Nasdaq OMXOct 1, 2016, 7:05 AM UTC
BusinessDermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology CongressBy Nasdaq OMXSep 28, 2016, 11:30 AM UTC
BusinessDermira Licenses DRM04 to Maruho for Hyperhidrosis in JapanBy Nasdaq OMXSep 20, 2016, 8:05 PM UTC
BusinessDermira Acquires Option to License Exclusive Rights for up to Three Early-Stage Programs from TakedaBy Nasdaq OMXSep 12, 2016, 11:30 AM UTC
BusinessDermatology Diagnostic Devices and Therapeutics Market - Increasing geriatric population are driving the growth of market: MRRSEBy Nasdaq OMXApr 12, 2016, 1:00 PM UTC
BusinessDermira’s Co-founder and Chief Medical Officer, Eugene A. Bauer, M.D., Receives Presidential Citation from the American Academy of DermatologyBy Nasdaq OMXMar 14, 2016, 11:30 AM UTC
